Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Tumor Marker Testing Market Growth Potential: How Will Market Size Change Through 2030?

The market for tumor marker testing has experienced robust expansion recently, projecting a rise from $18.6 billion in 2025 to $20.12 billion in 2026, fueled by a compound annual growth rate (CAGR) of 8.2%. This historical growth trajectory is attributable to a confluence of factors including escalating cancer prevalence, heightened adoption of oncological laboratory diagnostics, the proliferation of cancer testing services within hospitals, the existence of well-recognized biochemical markers, and the expansion of diagnostic laboratory networks.

The global market for tumor marker testing is poised for significant expansion, projecting a valuation of $27.23 billion by 2030, exhibiting a compound annual growth rate of 7.9%. This anticipated upward trajectory is primarily fueled by an escalating need for the early identification of cancer, a broader embrace of precision oncology methodologies, the proliferation of companion diagnostics, the increasing utility of biomarkers in guiding therapeutic choices, and ongoing breakthroughs in cancer biomarker research. Key developments expected to shape this market during the forecast period encompass a greater utilization of combined tumor marker testing panels, a rise in the adoption of blood-based diagnostic tools for cancer, a more profound integration of tumor markers into the process of monitoring treatment efficacy, the widening scope of early cancer detection initiatives, and a heightened emphasis on individualized cancer care strategies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20668&type=smp

Tumor Marker Testing Market Demand Drivers: What Is Fueling Industry Growth?

The escalating incidence of cancer is anticipated to be a significant catalyst for the expansion of the tumor marker testing sector. Cancer, defined by the aberrant proliferation of cells that can infiltrate adjacent tissues and metastasize throughout the body via circulatory and lymphatic pathways, is becoming more widespread. Contributing to this upward trend in cancer diagnoses are demographic shifts like an aging populace, heightened exposure to environmental factors, evolving lifestyles, and advancements in diagnostic capabilities. Tumor marker tests play a crucial role in the management of numerous cancers, aiding in their identification, assessing therapeutic efficacy, and identifying recurrence by quantifying distinct biological substances indicative of malignancy. Supporting this, the National Health Service, a UK governmental body, reported that in 2023, 354,820 new cancer cases were identified, averaging 972 daily, an increase of 8,605 cases compared to the previous year. Consequently, the rising burden of cancer directly fuels the growth of the market for tumor marker diagnostics.

Tumor Marker Testing Market Segment Performance And Strategic Opportunities

The tumor marker testing market covered in this report is segmented –

1) By Product: Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines

2) By Methods: Screening, Imaging, Theranostics, Other Methods

3) By Application: Hospitals, Commercial Or Private Laboratories, Physician Offices Or Group Practices, Cancer Clinics, Ambulatory Care Centers

Subsegments:

1) By Biochemical Markers: Alpha-fetoprotein (AFP), Prostate-Specific Antigen (PSA), Carcinoembryonic Antigen (CEA), Cancer Antigen 125 (CA 125), Cancer Antigen 19-9 (CA 19-9), Human Chorionic Gonadotropin (hCG)

2) By Oncogenes: HER2 Or neu, KRAS, BRAF, EGFR (Epidermal Growth Factor Receptor), c-MYC, p53

3) By Growth Factors: Vascular Endothelial Growth Factor (VEGF), Platelet-Derived Growth Factor (PDGF), Transforming Growth Factor-beta (TGF-β), Fibroblast Growth Factor (FGF), Insulin-like Growth Factor (IGF)

4) By Hormones: Estrogen Receptors (ER), Progesterone Receptors (PR), Thyroglobulin, Calcitonin, Adrenocorticotropic Hormone (ACTH), Gastrin

5) By Colony Stimulating Factors: Granulocyte Colony-Stimulating Factor (G-CSF), Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Macrophage Colony-Stimulating Factor (M-CSF)

6) By Lymphokines: Interleukin-2 (IL-2), Interferon-gamma (IFN-γ), Tumor Necrosis Factor-alpha (TNF-α), Interleukin-6 (IL-6)

Tumor Marker Testing Market Innovation Trends: Which Developments Are Transforming The Industry?

Companies dominant in the tumor marker testing sector are directing greater attention toward the creation of sophisticated tests, specifically molecular testing options, as a means to secure a more advantageous position within the marketplace. Molecular testing solutions encompass cutting-edge diagnostic approaches that scrutinize genetic material, including DNA and RNA, for the identification of alterations, infectious agents, or particular biomarkers at a fundamental molecular level. As an illustration, during April 2024, RGCC International GmbH, a Swiss entity engaged in personalized cancer therapies, introduced Onco-D-clare, a pioneering test designed for cancer detection. This novel test empowers individuals to identify cancer manifestation prior to the onset of visible symptoms, by ingeniously integrating principles of molecular biology with artificial neural networks. The operational mechanism of Onco-D-clare involves separating peripheral blood mononuclear cells from collected blood specimens, followed by an in-depth examination of gene expression patterns across a spectrum exceeding ninety genes.

Tumor Marker Testing Market Key Players: Which Companies Shape Industry Competition?

Major companies operating in the tumor marker testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche AG, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson and Company (BD), Quest Diagnostics Inc., Agilent Technologies Inc, Hologic Inc., Illumina Inc., bioMérieux SA, Bio-Rad Laboratories Inc., Qiagen N.V., DiaSorin S.p.A., Myriad Genetics, Ortho Clinical Diagnostics PLC, Veracyte Inc., Biodesix Inc., Biocept Inc., Proteomedix AG, OncoCyte Corporation, Biocartis NV

Access The Complete Tumor Marker Testing Market Report:

https://www.thebusinessresearchcompany.com/report/tumor-marker-testing-global-market-report

Tumor Marker Testing Market Regional Analysis: Which Region Leads By Revenue?

North Americawas the largest region in the tumor marker testing market in 2025. The regions covered in the tumor marker testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model